Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
RESEARCH LETTER
Sodium-glucose cotransporter 2 inhibitors and kidney stones: a Mendelian randomisation study
1
Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
2
Department of Cardiac Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China
3
National Clinical Research Centre for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China
These authors had equal contribution to this work
Submission date: 2026-05-07
Final revision date: 2026-09-10
Acceptance date: 2026-10-13
Online publication date: 2026-10-23
Corresponding author
Zhitao Dong
Department of Urology The Second Xiangya Hospital Central South University No. 139 Renmin Road Changsha 410011 China
Department of Urology The Second Xiangya Hospital Central South University No. 139 Renmin Road Changsha 410011 China
KEYWORDS
TOPICS
ABSTRACT
Introduction:
NA
Material and methods:
NA
Results:
NA
Conclusions:
NA
NA
Material and methods:
NA
Results:
NA
Conclusions:
NA
REFERENCES (18)
1.
Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 2010; 12: e86-96.
2.
Cherney DZ, Odutayo A, Aronson R, Ezekowitz J, Parker JD. Sodium glucose cotransporter-2 inhibition and cardiorenal protection: JACC review topic of the week. J Am Coll Cardiol 2019; 74: 2511-24.
3.
Bernardi M, Spadafora L, Galli M, Biondi-Zoccai G, Sabouret P. Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients? Arch Med Sci 2023; 19: 528-31.
4.
Anan G, Hirose T, Kikuchi D, et al. Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation. Pharmacol Res 2022; 186: 106524.
5.
Paik JM, Tesfaye H, Curhan GC, Zakoul H, Wexler DJ, Patorno E. Sodium-glucose cotransporter 2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes. JAMA Intern Med 2024; 184: 265-74.
6.
Cosentino C, Dicembrini I, Nreu B, Mannucci E, Monami M. Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 2019; 155: 107808.
7.
Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA 2017; 318: 1925-6.
8.
Guo X, Gao F, Pan B, et al. Causal association of plasminogen activators and their inhibitors with Alzheimer’s disease: a Mendelian randomization study. Arch Med Sci 2025; 21: 1323-31.
9.
Carter AR, Sanderson E, Hammerton G, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol 2021; 36: 465-78.
10.
Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol 2011; 40: 740-52.
11.
Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015; 44: 512-25.
12.
Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 2016; 40: 304-14.
13.
Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement. JAMA 2021; 326: 1614-21.
14.
Kristensen KB, Henriksen DP, Hallas J, Pottegård A, Lund LC. Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis. Diabetologia 2021; 64: 1563-71.
15.
Balasubramanian P, Wanner C, Ferreira JP, et al. Empagliflozin and decreased risk of nephrolithiasis: a potential new role for SGLT2 inhibition? J Clin Endocrinol Metab 2022; 107: e3003-7.
16.
Qian S, Liang S, Yu H. Leveraging genetic interactions for adverse drug-drug interaction prediction. PLoS Comput Biol 2019; 15: e1007068.
17.
Almuhanna NR, Alhussain AM, Aldamanhori RB, Alabdullah QA. Association of chronic hyperglycemia with the risk of urolithiasis. Cureus 2023; 15: e47385.
18.
Cameron MA, Maalouf NM, Adams-Huet B, Moe OW, Sakhaee K. Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol 2006; 17: 1422-8.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
